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USE OF PARTHENOLIDE DERIVATIVES AS 
ANTILEUKEMIC AND CYTOTOXIC AGENTS 
This is a divisional application of US. patent application 
Ser. No. 12/693,161, ?led Jan. 25, 2010, now US. Pat. No. 
8,124,652, which is a divisional application of US. patent 
application Ser. No. 11/031,315 ?led Jan. 7, 2005, now US. 
Pat. No. 7,678,904, which is a continuation-in-part of US. 
patent application Ser. No. 10/888,274 ?led Jul. 9, 2004, now 
US. Pat. No. 7,312,242, which claims the bene?t of priority 
to provisional application No. 60/486,171 ?led Jul. 11, 2003. 
FIELD OF THE INVENTION 
The present invention relates to methods for the structural 
modi?cation of the sesquiterpene lactone, parthenolide, and 
the use of these parthenolide derivatives in the treatment of 
carcinoma. More speci?cally, the invention relates to the 
methods to prepare structural analogs of the parent com 
pound, parthenolide, in order to obtain new, pharmacologi 
cally active chemical entities with improved water solubility 
characteristics, and to use them in the treatment of leukemias 
and other parental and multi-drug resistant cancers 
BACKGROUND OF THE INVENTION 
Sesquiterpene lactones are a group of secondary plant 
metabolites consisting of a 15-carbon structure containing an 
(x-methylene-y-butyrolactone moiety and other additional 
functional groups. Over the last two to three decades, these 
terpenoids have received considerable attention due to the 
broad spectrum of their biological activities, to the plants 
which produce them, and most importantly, because of their 
pharmacological effects in humans. About 4,000 of these 
terpenoids have been isolated and identi?ed, most of them in 
Asteraceae (Compositae, sun?ower family) (Schmidt, Curr. 
Org. Chem. 1999, 3, 577-608). Some of these plants have 
been used for centuries in indigenous medical practices in 
various cultures worldwide. 
Parthenolide (1) is a Germacrane sesquiterpene lactone 
with a unique structure. It has been isolated from several 
different species in Asteraceae (Compositae) family, fever 
few (Tanacetum parthenium) being one of them. 
Feverfew has been used to reduce fever and pain and in the 
treatment of mi graine and rheumatoid arthritis (Heptinstall et 
al., ACS Symposium Series (1998), 691 (Phytomedicines of 
Europe), 158-175.). The active component is parthenolide 
(1). Recently, it has been revealed that parthenolide (1) can 
induce tumor apoptosis by the inhibition of NF-KB activities 
(Cory et al., Anticancer Research 2002, 22, 3805-9; Cory et 
al., Anticancer Research 2001, 21, 3807-11; Gelfanov et al., 
Blood, 2000, 98, 2508-17; Kang et al, Brit. J. Pharmacol. 
2002, 135, 1235-44; Song et al., J. Asian. Nat. Prod. Res. 
2001, 3, 285-91). 
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Parthenolide (1) is a lipophilic, neutral lactone with low 
polarity, and has a low water-solubility, limiting its develop 
ment as a therapeutic agent. Thus, a need exists for the devel 
opment of soluble parthenolide derivatives that retain their 
anti-cancer activity. 
SUMMARY OF THE INVENTION 
In accordance with the present invention, a novel class of 
compounds with antileukemic activity is presented. Accord 
ingly, the present invention provides compounds of formula 
(I): 
(I) 
wherein: 
X1, X2 and X3 are heteroatoms; 
R4, R5, R6, R7, R8, R9 and R10 are independently selected 
from H, halo, 40H, iNOZ, 4CN and optionally substi 
tuted aliphatic, cycloalkyl, heterocycloalkyl, aryl or het 
eroaryl; and 
Z is optionally substituted C 1_8 straight-chained or branched 
aliphatic, optionally containing 1 or more double or triple 
bonds, wherein one or more carbons are optionally replaced 
by R* wherein R* is optionally substituted cycloalkyl, het 
erocycloalkyl, aryl or heteroaryl; an amino acid residue, H, 
4CN, iC(O)i, 4C(O)C(O)i, 4C(O)NRli, 4C(O) 
NRlNRzi, iC(O)Oi, wqok, iNRlCOZi, 
wi, iNR1C(O)NRZi, iOC(O)NRli, iNRlNRZi, 
iNRlC(O)i, isi, isoi, isor, iNRli, 
iSOzNRli, iNRlR2, or iNRlSOZi, wherein R1 and 
R2 are independently selected from H and optionally substi 
tuted aliphatic, cycloalkyl, heterocycloalkyl, aryl or het 
eroaryl; or where R* is NRIRZ, R1 and R2 optionally together 
with the nitrogen atom form an optionally substituted 5-12 
membered ring, said ring optionally comprising 1 or more 
heteroatoms and/or a group selected from iCOi, iSOi, 
iSOZi and iPOi; or 
a pharmaceutically acceptable salt, ester or prodrug 
thereof. 
The invention also provides a pharmaceutical composition 
comprising an effective amount of a compound of formula (I), 
or a pharmaceutically acceptable salt, ester or prodrug 
thereof, in combination with a pharmaceutically acceptable 
diluent or carrier. 
The invention also provides a method of inhibiting cancer 
cell growth and metastasis of cancer cells, comprising admin 
istering to a mammal af?icted with cancer, an amount of a 
compound of formula (I), effective to inhibit the growth of 
said cancer cells. 
The invention also provides a method comprising inhibit 
ing cancer cell growth by contacting said cancer cell in vitro 
or in vivo with an amount of a compound of formula (I), 
effective to inhibit the growth of said cancer cell. 
The invention also provides a compound of formula (I) for 
use in medical therapy (preferably for use in treating cancer, 
e.g. solid tumors), as well as the use of such compound for the 
US 8,470,875 B2 
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manufacture of a medicament useful for the treatment of 
cancer and other diseases/ disorders described herein. 
The invention further provides methods of treating in?am 
matory diseases and disorders, including, for example, rheu 
matoid arthritis, osteoarthritis, allergies (such as asthma), and 
other in?ammatory conditions, such as pain (such as 
migraine), swelling, fever, psoriasis, in?ammatory bowel dis 
ease, gastrointestinal ulcers, cardiovascular conditions, 
including ischemic heart disease and atherosclerosis, partial 
brain damage caused by stroke, skin conditions (eczema, 
sunburn, acne), leukotriene-mediated in?ammatory diseases 
of lungs, kidneys, gastrointestinal tract, skin, prostatitis and 
paradontosis. 
The invention further provides methods of treating 
immune response disorders, whereby the immune response is 
inappropriate, excessive or lacking. Such disorders include 
allergic responses, transplant rejection, blood transfusion 
reaction, and autoimmune disorders such as systemic lupus 
erythematosus and rheumatoid arthritis. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows the effectiveness of parthenolide and deriva 
tives of the present invention against prostate cancer cell line 
CWR22 in a clonogenic assay. 
FIG. 2 shows the effectiveness of parthenolide and deriva 
tives of the present invention against lung cancer cell line 
A-549 in a cellular proliferation MTS-PMS assay. 
FIG. 3 shows the effectiveness of parthenolide and deriva 
tives of the present invention against lung cancer cell line 
H-522 in a cellular proliferation MTS-PMS assay. 
FIG. 4 shows the effectiveness of parthenolide and deriva 
tives of the present invention against lung cancer cell line 
H-23 in a cellular proliferation MTS-PMS assay. 
FIG. 5 shows the effectiveness of parthenolide and deriva 
tives of the present invention against lung cancer cell line 
H-460 in a cellular proliferation MTS-PMS assay. 
FIG. 6 shows the effectiveness of parthenolide and deriva 
tives of the present invention against breast cancer cell line 
HBL-lOO in a clonogenic assay. 
FIG. 7 shows the effectiveness of parthenolide and deriva 
tives of the present invention against breast cancer cell line 
MD-23l in a clonogenic assay. 
FIG. 8 shows the effectiveness of parthenolide and deriva 
tives of the present invention against breast cancer cell line 
MD-436 in a clonogenic assay 
FIG. 9 shows parthenolide and DMAPT plasma concen 
trations at one hour following oral gavage in mice. 
FIG. 10 shows DMAPT dose-dependent inhibition of NF 
kB DNA binding in two transitional cell carcinoma cell lines 
HT-l376 and UMUC-3 in electrophoretic mobility gel shift 
assay (EMSA). 
FIG. 11 shows FSCScan analysis of TRAIL induced apo 
ptosis assay using MDA-MB-23l breast cancer cells treated 
?rst with DMAPT, then TRAIL-RII-activating antibodies. 
FIG. 12 shows FSCScan analysis of TRAIL induced apo 
ptosis assay using MDA-MB-23l breast cancer cells treated 
?rst with DMAPT, then TRAIL. 
DETAILED DESCRIPTION OF THE INVENTION 
As used herein, the following de?nitions shall apply unless 
otherwise indicated. 
The phrase “optionally substituted” is used interchange 
ably with the phrase “substituted or unsubstituted.” Unless 
otherwise indicated, an optionally substituted group may 
have a substituent at each substitutable position of the group, 
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4 
and each substitution is independent of any other. Also, com 
binations of substituents or variables are permissible only if 
such combinations result in stable compounds. In addition, 
unless otherwise indicated, functional group radicals are 
independently selected. Where “optionally substituted” 
modi?es a series of groups separated by commas (e. g., 
“optionally substituted A, B or C”; or “A, B or C optionally 
substituted with”), it is intended that each of the groups (e. g., 
A, B and C) is optionally substituted. 
The term “aliphatic” or “aliphatic group” as used herein 
means a straight-chain or branched C 1_l 2 hydrocarbon chain 
that is completely saturated or that contains one or more units 
of unsaturation, or a monocyclic C3_8 hydrocarbon orbicyclic 
C8_12 hydrocarbon that is completely saturated or that con 
tains one or more units of unsaturation, but which is not 
aromatic (also referred to herein as “carbocycle” or 
“cycloalkyl”), that has a single point of attachment to the rest 
of the molecule wherein any individual ring in said bicyclic 
ring system has 3-7 members. For example, suitable aliphatic 
groups include, but are not limited to, linear or branched or 
alkyl, alkenyl, alkynyl groups and hybrids thereof such as 
(cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alk 
enyl. 
The terms “alkyl,” “alkoxy,” “hydroxyalkyl,” “alkoxy 
alkyl” and “alkoxycarbonyl,” used alone or as part of a larger 
moiety include both straight and branched chains containing 
one to twelve carbon atoms. The terms “alkenyl” and “alky 
nyl” used alone or as part of a larger moiety shall include both 
straight and branched chains containing two to twelve carbon 
atoms. 
The terms “haloalkyl,” “haloalkenyl” and “haloalkoxy” 
means alkyl, alkenyl or alkoxy, as the case may be, substituted 
with one or more halogen atoms. The term “halogen” or 
“halo” means F, Cl, Br or I. 
The term “heteroatom” means nitrogen, oxygen, or sulfur 
and includes any oxidized form of nitrogen and sulfur, and the 
quatemized form of any basic nitrogen. Heteroatom further 
includes Se, Si and P. 
The term “aryl” used alone or in combination with other 
terms, refers to monocyclic, bicyclic or tricyclic carbocyclic 
ring systems having a total of ?ve to fourteen ring members, 
wherein at least one ring in the system is aromatic and 
wherein each ring in the system contains 3 to 8 ring members. 
The term “aryl” may be used interchangeably with the term 
“aryl ring”. The term “aralkyl” refers to an alkyl group sub 
stituted by an aryl. The term “aralkoxy” refers to an alkoxy 
group substituted by an aryl. 
The term “heterocycloalkyl,” “heterocycle,” “heterocy 
clyl” or “heterocyclic” as used herein means monocyclic, 
bicyclic or tricyclic ring systems having ?ve to fourteen ring 
members in which one or more ring members is a heteroatom, 
wherein each ring in the system contains 3 to 7 ring members 
and is non-aromatic. 
The term “heteroaryl,” used alone or in combination with 
other terms, refers to monocyclic, bicyclic and tricyclic ring 
systems having a total of ?ve to fourteen ring members, and 
wherein: l) at least one ring in the system is aromatic; 2) at 
least one ring in the system contains one or more heteroatoms; 
and 3) each ring in the system contains 3 to 7 ring members. 
The term “heteroaryl” may be used interchangeably with the 
term “heteroaryl ring” or the term “heteroaromatic”. 
Examples of heteroaryl rings include 2-furanyl, 3-furanyl, 
N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 
3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxadiazolyl, 
5-oxadiazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, l-pyrro 
lyl, 2-pyrrolyl, 3-pyrrolyl, l-pyrazolyl, 3-pyrazolyl, 4-pyra 
zolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrim 
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idyl, 5-pyrimidyl, 3-pyridaZinyl, 2-thiazolyl, 4-thiazolyl, 
5-thiazolyl, 5-tetrazolyl, 2-triazolyl, 5-triazolyl, 2-thienyl, 
3-thienyl, carbazolyl, benZimidazolyl, benzothienyl, benzo 
furanyl, indolyl, quinolinyl, benzotriazolyl, benzothiazolyl, 
benzooxazolyl, benZimidazolyl, isoquinolinyl, indazolyl, 
isoindolyl, acridinyl, and benzoisoxazolyl. The term “het 
eroaralkyl” refers to an alkyl group substituted by a het 
eroaryl. The term “heteroarylalkoxy” refers to an alkoxy 
group substituted by a heteroaryl. \ 
An aryl (including aralkyl, aralkoxy, aryloxyalkyl and the 
like) or heteroaryl (including heteroaralkyl, heteroarylalkoxy 
and the like) group may contain one or more substituents. 
Suitable substituents on an unsaturated carbon atom of an 
aryl, heteroaryl, aralkyl or heteroaralkyl group are selected 
from halogen; haloalkyl; 4CF3; iR; iOR; iSR; 1,2 
methylenedioxy; 1,2-ethylenedioxy; protected OH (such as 
acyloxy); phenyl (Ph); Ph substituted with R; iO(Ph); *0 
(Ph) substituted with R; 4CH2(Ph); 4CH2(Ph) substituted 
with R; iCHZCH2(Ph); iCHzCH2(Ph) substituted with R; 
iNOZ; %N; iN(R)2; *NRC(O)R; iNRC(O)N(R)2; 
i(CH2)yNHC(O)R; i(CH2)yR; i(CH2)yNHC(O)NHR; 
i(CH2)yNHC(O)OR; i(CH2)yNHS(O)R; i(CH2)y 
NHSOZR; or i(CH2)yNHC(O)CH((V)ZiR)(R) wherein 
each R is independently selected from hydrogen, optionally 
substituted Cl_6 aliphatic, an unsubstituted 5-6 membered 
heteroaryl or heterocyclic ring, phenyl (Ph), 40(Ph), or 
iCH2(Ph)-CH2(Ph), wherein y is 0-6; Z is 0-1; and V is a 
linker group. When R is C 16 aliphatic, it may be substituted 
with one or more substituents selected from iNHZ, iNH 
(C 1_ 4 aliphatic), iN(C1_4 aliphatic)2, iS(O)(Cl_4 aliphatic), 
iSOZ(C1_4 aliphatic), halogen, (Cl_4 aliphatic), iOH, 
iO(Cl_4 aliphatic), iNOZ, iCN, iCO2H, 4COZ(C1_4 
aliphatic), 40(halo C1_4 aliphatic), or -halo(Cl_4 aliphatic); 
wherein each C1_4 aliphatic is optionally. 
An aliphatic group or a non-aromatic heterocyclic ring 
may contain one or more substituents. Suitable substituents 
on a saturated carbon of an aliphatic group or of a non 
aromatic heterocyclic ring are selected from those listed 
above for the unsaturated carbon of an aryl or heteroaryl 
group and the following: :0, :S, :NNHR, :NN(R)2, 
:Ni, :NNHC(O)R, :NNHCOZ(alkyl), :NNHSO2 
(alkyl), or :NR, where each R is independently selected 
from hydrogen or an optionally substituted C1_6 aliphatic. 
When R is Cl_6 aliphatic, it may be substituted with one or 
more substituents selected from iNHZ, iNH(Cl_4 ali 
phatic), iN(C1_4 aliphatic)2, halogen, 40H, iOi(Cl_4 
aliphatic), iNOZ, 4CN, iCOZH, 4COZ(C1_4 aliphatic), 
iO(halo C1_4 aliphatic), or -halo(Cl_4 aliphatic); wherein 
each C 1_ 4 aliphatic is optionally substituted. 
Substituents on a nitrogen of a non-aromatic heterocyclic 
ring are selected from 
iR, iN(R)2, iC(O)R, iC(O)OR, 4C(O)C(O)R, 
iC(O)CH2C(O)R, iSOZR, iSOZN(R)2, 4C(:S)N(R)2, 
iC(:NH)iN(R)2 or iNRSOZR; wherein each R is inde 
pendently selected from hydrogen, an optionally substituted 
Cl_6 aliphatic, optionally substituted phenyl (Ph), optionally 
substituted 40(Ph), optionally substituted 4CH2(Ph), 
optionally substituted 4CH2CH2(Ph), or an unsubstituted 
5-6 membered heteroaryl or heterocyclic ring. When R is a 
C1_6 aliphatic group or a phenyl ring, it may be substituted 
with one or more substituents selected from iNHZ, iNH 
(Cl_4 aliphatic), iN(C1_4 aliphatic)2, halogen, i(Cl_4 ali 
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phatic), iOH, 4Oi(Cl_4 aliphatic), iNOZ, iCN, 
4CO2H, iCO2(Cl_4 aliphatic), iO(halo Cl_4 aliphatic) 
or -halo(C1_4 aliphatic); wherein each C1_4 aliphatic is option 
ally substituted. 
The term “linker group” or “linker” means an organic 
moiety that connects two parts of a compound. Linkers 
include alkylidene chain that is a saturated or unsaturated, 
straight or branched, C1_8 carbon chain which is optionally 
substituted, and wherein up to two non-adjacent saturated 
carbons of the chain are optionally replaced by R* wherein 
R* is %(O)i, %(O)C(O)i, iC(O)NRi, %(O) 
NRNRi, %(O)Oi, iOC(O)i, iNRCOZi, ADi, 
iNRC(O)NRi, iOC(O)NRi, iNRNRi, iNRC 
(O)i, iSi, iSOi, iSOZi, iNRi, iSOZNRi, or 
iNRSOZi; wherein R is selected from hydrogen or option 
ally substituted aliphatic, cycloalkyl, heterocycloalkyl, aryl 
or heteroaryl, and preferably H or optionally substituted C l_4 
aliphatic. Optional substituents on the alkylidene chain are as 
described above for an aliphatic group. Alternatively, the 
linker group is R*. 
The term “treatment” refers to any treatment of a patho 
logic condition in a mammal, particularly a human, and 
includes: (i) preventing the pathologic condition from occur 
ring in a subject which may be predisposed to the condition 
but has not yet been diagnosed with the condition and, accord 
ingly, the treatment constitutes prophylactic treatment for the 
disease condition; (ii) inhibiting the pathologic condition, 
i.e., arresting its development; (iii) relieving the pathologic 
condition, i.e., causing regression of the pathologic condi 
tion; or (iv) relieving the conditions mediated by the patho 
logic condition. 
The term “therapeutically effective amount” refers to that 
amount of a compound of the invention that is suf?cient to 
effect treatment, as de?ned above, when administered to a 
mammal in need of such treatment. The therapeutically effec 
tive amount will vary depending upon the subject and disease 
condition being treated, the weight and age of the subject, the 
severity of the disease condition, the manner of administra 
tion and the like, which can readily be determined by one of 
ordinary skill in the art. 
The term “pharmaceutically acceptable salts” includes, but 
is not limited to, salts well known to those skilled in the art, for 
example, mono-salts (e.g. alkali metal and ammonium salts) 
and poly salts (e.g. di- or tri-salts,) of the compounds of the 
invention. Pharmaceutically acceptable salts of compounds 
of formulas (I), (II), (III), or (IV) are where, for example, an 
exchangeable group, such as hydrogen in iOH, iNHi, or 
iP(:O)(OH)i, is replaced with a pharmaceutically 
acceptable cation (e.g. a sodium, potassium, or ammonium 
ion) and can be conveniently be prepared from a correspond 
ing compound of formula (I) by, for example, reaction with a 
suitable base. In cases where compounds are suf?ciently 
basic or acidic to form stable nontoxic acid or base salts, 
administration of the compounds as salts may be appropriate. 
Examples of pharmaceutically acceptable salts are organic 
acid addition salts formed with acids that form a physiologi 
cal acceptable anion, for example, tosylate, methane 
sulfonate, acetate, citrate, malonate, tartarate, succinate, ben 
zoate, ascorbate, (x-ketoglutarate, and (x-glycerophosphate. 
Suitable inorganic salts may also be formed, including hydro 
chloride, sulfate, nitrate, bicarbonate, and carbonate salts. 
Pharmaceutically acceptable salts include quaternary 
ammonium salts formed with R'Y; where Y is selected from 
halogen, tosylate, methanesulfonate, benzenesulfonate, trif 
luoromethanesulfonate and the like; and R' is selected from 
an optionally substituted cycloalkyl, heterocycloalkyl, aryl or 
heteroaryl. 
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Suitable acids include hydro?uoric acid, hydrochloric 
acid, hydrobromic acid, hydriodic acid, sulfuric acid, nitric 
acid, phosphoric acid, carbonic acid, boric acid, selenious 
acid, hydrogen sul?de, phosphomolybdic acid, phosphorous 
acid, sulfurous acid, citric acid, maleic acid, D-malic acid, 
L-lactic acid, D-lactic acid, DL-lactic acid, oxalic acid, meth 
anesulfonic acid, valeric acid, oleic acid, lauric acid, para 
toluenesulfonic acid, 1-naphthalensulfonic acid, 2-naphtha 
lensulfonic acid, phthalic acid, tartaric acid, L-malic acid, 
DL-malic acid, malonic acid, succinic acid, fumaric acid, 
glycolic acid, thioglycolic acid, glycine, sarcocine, sulfonic 
acid, nicotinic acid, picolinic acid, isonicotinic acid, benzoic 
acid and substituted benzoic acid where benzene ring bears 
one or more substituents. 
Pharmaceutically acceptable salts may be obtained using 
standard procedures well known in the art, for example, by 
reacting a suf?ciently basic compound such as an amine with 
a suitable acid affording a physiologically acceptable anion. 
Alkali metal (for example, sodium, potassium or lithium) or 
alkaline earth metal (for example, calcium) salts of carboxy 
lic acids can also be made. 
The term “prodrug” or “prodrugs” is used in its ordinary 
meaning in the art and means a compound of the invention 
that has its charged moieties masked or protected by another 
moiety that is designed to be cleaved under particular physi 
ological conditions, leaving the deprotected or unmasked 
compound of the invention. The use of masking agents is 
common and well-known in the art and, in particular, masking 
phosphate or phosphonate groups. All such masking agents 
are suitable and can be used with the compounds of the 
invention. Various agents such as acyloxy alkyl esters are 
described by Srivasta et al., (1984 Bioorganic Chemistry 12, 
118-12), and by Freeman et al. (1997 Progress in Medicinal 
Chemistry 34:112-147) which are each incorporated in their 
entirety herein by reference; and 3-phthalidyl phosphonate 
esters are described by Dang Q, et al., (1999 Bioorganic & 
Med. Chem. Letters, 9:1505-1510), which is incorporated in 
its entirety herein by reference. For example, and not by way 
of limitation, Srivasta et al. also describe acetoxymethyl, 
isobutryloxymethyl, and pivaloxymethyl as masking agents. 
Other suitable masking groups comprising pivaloxyalkyl, 
e.g., pivaloxymethyl, or a pivaloyloxy group as described by 
Farquhar D. et al., (1995 J. Med. Chem., 38:488-495) which 
is incorporated in its entirety herein by reference. Still other 
masking or protecting agents are described in US. Pat. Nos. 
4,816,570 and 4,968,788 both of which are incorporated in 
their entirety herein by reference. Lipid prodrugs are also 
suitable for use with the compounds of the invention. By 
non-limiting example, certain lipid prodrugs are described in 
Hostetler et al., (1997 Biochem. Pharm. 53:1815-1822), and 
Hostetler et al., 1996 Antiviral Research 31:59-67), both of 
which are incorporated in their entirety herein by reference. 
Additional examples of suitable prodrug technology is 
described in WO 90/00555; WO 96/39831; WO 
03/095665A2; US. Pat. Nos. 5,411,947; 5,463,092; 6,312, 
662; 6,716,825; and US. Published Patent Application Nos. 
2003/0229225 and 2003/0225277 each of which is incorpo 
rated in their entirety herein by reference. Such prodrugs may 
also possess the ability to target the drug compound to a 
particular tissue within the patient, e.g., liver, as described by 
Erion et al., (2004 J. Am. Chem. Soc. 126:5154-5163; Erion et 
al., Am. Soc. Pharm. & Exper. Ther. DOI: 10.1124/ 
jept.104.75903 (2004); WO 01/18013 A1; US. Pat. No. 
6,752,981), each of which is incorporated in their entirety 
herein by reference. By way of non-limiting example, other 
prodrugs suitable foruse with the compounds of the invention 
are described in WO 03/090690; and by Harris et al., (2002 
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Antiviral Chem & Chemo. 12: 293-300; Knaggs et al., 2000 
Bioorganic & Med. Chem. Letters 10: 2075-2078) each of 
which is incorporated in their entirety herein by reference. 
The invention relates to the ability of the (x-methylene-y 
butyrolactone moiety in sesquiterpene lactones to be struc 
turally modi?ed by, for example, Michael addition with 
amines or thiols. Modi?cation of the parthenolide (1) mol 
ecule by this methodology using primary and/or secondary 
amines to form water-soluble amino derivatives, affords 
amine adducts that can easily be obtained as different inor 
ganic or organic salts to further increase water solubility. 
Thus, a novel class of more water-soluble parthenolide ana 
logs is described. When compounds in this class were evalu 
ated for antileukemic activity, it was found that these com 
pounds were either equipotent as, or more potent than the 
parent compound, parthenolide. More importantly, these 
novel analogs showed greater cytotoxicity towards leukemia 
cells than towards normal cells. Thus, the present invention 
provides a new class of parthenolide derivatives with potent 
and selective anticancer activities. 
In accordance with the present invention, there are pro 
vided compounds of formula (I): 
(I) 
wherein: 
X1, X2 and X3 are heteroatoms; 
R4, R5, R6, R7, R8, R9 and R10 are independently selected 
from H, halo, 40H, iNOZ, 4CN and optionally substi 
tuted aliphatic, cycloalkyl, heterocycloalkyl, aryl or het 
eroaryl; and 
Z is optionally substituted Cl_8 straight-chained or 
branched aliphatic, optionally containing 1 or more double or 
triple bonds, wherein one or more carbons are optionally 
replaced by R* wherein R* is optionally substituted 
cycloalkyl, heterocycloalkyl, aryl or heteroaryl; an amino 
acid residue, H, 4CN, iC(O)i, iC(O)C(O)i, 4C(O) 
NRli, iC(O)NR1NRZi, %(0)oi, wqok, 
iNRlCOZi, 40*, iNR1C(O)NRZi, iOC(O)NRli, 
iNRlNRZi, iNRlC(O)i, isi, isoi, isozi, 
iNRli, iSOZNRli, iNRlRZ, or iNRlSOzi, 
wherein R1 and R2 are independently selected from H and 
optionally substituted aliphatic, cycloalkyl, heterocycloalkyl, 
aryl or heteroaryl; or where R* is NR1R2, R1 and R2 option 
ally together with the nitrogen atom form an optionally sub 
stituted 5-12 membered ring, said ring optionally comprising 
1 or more heteroatoms and/ or a group selected from 4COi, 
iSOi, iSOZi and iPOi; or 
a pharmaceutically acceptable salt, ester or prodrug 
thereof. 
Presently preferred compounds include compounds of for 
mula (I) wherein R5, R6, R7, R9 and R10 are independently 
selected from H, halo, 40H, iNOZ, iCN, iCH3, 4CF3, 
%H2CH3, %H2CF3, %H2Cl, %HZOH, 
4CH2CHZOH and 4CH2NH2. Further preferred embodi 
ments include compounds where R5, R6, R7, R9 and R10 are 
each H. 
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Other preferred embodiments of the present invention 
include compounds Where R4 and R8 are independently 
selected from optionally substituted Cl-C4 alkyl. In one pre 
ferred embodiment, R4 is 4CH3, and in another, R4 and R8 
are each 4CH3. 
In one embodiment X1, X2 and X3 are heteroatoms inde 
pendently selected from O, N and S, and in one particular 
embodiment, X1, X2 and X3 are each 0. 
According to one embodiment, it is preferred that Where 
R5, R6, R7, R9 and R10 are H, R4 and R8 are each iCH3, and 
X1, X2 and X3 are each 0; Z is not :CHZ. 
According to a further embodiment of the invention, Z is 
i(CH2)miNR1R2 Where m is an integer from 0 to 4, Where 
preferably, R5, R6, R7, R9, and R10 are H; and R4 and R8 are 
each 4CH3. In one particular embodiment, m is 1. In other 
embodiments, R1 and R2 are independently selected from 
hydrogen, 4CN or optionally substituted C l-C4 alkyl. In 
particular embodiments, R1 and R2 are independently 
selected from iNOZ, 4CN, 4CH3, iCF3, iCHZCH3, 
iCHZCF3, iCHzCl, iCHzOH, iCHzCHzOH and 
iCHZNHZ. 
In yet a further embodiment, R1 and R2 together With N 
form an optionally substituted ring. The ring is a monocyclic, 
bicyclic or tricyclic aliphatic or aryl ring system, Where the 
ring system is optionally substituted and optionally com 
prises one or more heteroatoms or a group selected from 
iCOi, iSOi, iSOZi and iPOi. In one particular 
embodiment, R1 and R2 are iCH2(CH2)nCH2Yi, WhereY 
is a heteroatom or a group selected from 4COi, iSOi, 
iSOZi and iPOi; n is an integer 0 to 5; and together With 
N form an optionally substituted ring, Which may be addi 
tionally fused to a cycloalkyl or aryl group to form a bicyclic 
or tricyclic ring system, Where the system is optionally sub 
stituted and optionally comprises one or more heteroatoms. 
Alternatively, R1 and R2 are i(CH2)aiYi(CH2)bi, 
Where Y is a heteroatom or a group selected from 4COi, 
iSOi, iSOZi and iPOi; a is an integer 0 to 5; b is an 
integer 0 to 5; Where the sum of a and b is 0 to 5; and together 
With N form an optionally substituted ring, the ring being 
optionally fused to a cycloalkyl or aryl group to form a bicy 
clic or tricyclic ring system, Where the system is optionally 
substituted and optionally comprise one or more heteroat 
oms. 
Examples of ring systems include an optionally substituted 
uracil ring or a derivative thereof. Other examples include 
optionally substitute pyrrole, imidazole, purine and pyrazole 
and derivative thereof. Examples of fused ring systems 
include optionally substituted aZiridin-l-yl, azetidin-l-yl, 
pyrrolidin- l -yl, piperidin-l -yl, homopiperidyn- l -yl and hep 
tamethyleneimin- l -yl. 
According to a further embodiment of the invention, Z is 
i(CH2)miS(O)niRl Where m is an integer from 0 to 4, n is 
an integer from 0 to 2, Where preferably, R5, R6, R7, R9, and 
R10 are H; and R4 and R8 are each 4CH3. In one particular 
embodiment, m is 1. In another embodiment n is 0. In other 
embodiments, R1 is independently selected from hydrogen, 
iCN, optionally substituted C 1 -C4 alkyl or aryl. In particular 
embodiments, R1 is selected from iC6H5, iCHZCH 
(COZH)(NH2), and iCHZCO2H. 
Exemplary compounds of the present invention include: 
1 l S, l l , l 3 -Dihydro, l 3 -dimethylaminoparthenolide 
(DMAPT); 
l l S, l l , l 3-Dihydro, l 3-diethylaminoparthenolide; 
l l S, l l , l 3-Dihydro, l 3-(tert-butylamino)parthenolide; 
l l S, l l , l 3-Dihydro, l 3-(pyrrolidin-l -yl)parthenolide; 
l l S, l l , l 3-Dihydro, l 3-(piperidin-l -yl)parthenolide (PIPT); 
l l S, l 1,13 -Dihydro, l 3 -(morpholin- l -yl)parthenolide; 
l l S, l l , l 3-Dihydro, l 3-(4-methylpiperidin-l -yl)partheno 
lide (4MEPT); 
l l S, l l , l 3-Dihydro, l 3-(4-methylpiperaZin-l -yl)partheno 
lide; 
l l S, l l , l 3-Dihydro, l 3-(homopiperidin-l -yl)parthenolide; 
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l l S, l 1,13 -Dihydro, l 3-(heptamethyleneimin-l -yl)partheno 
lide; 
1 18,1 1,13 -Dihydro, l 3-(azetidin-l -yl)parthenolide; 
l l S, l l , l 3 -Dihydro, l 3-methylbutyl aminoparthenolide; 
l l S, l 1,13 -Dihydro, l 3-methyl pentyl aminoparthenolide; 
1 18,1 1,13 -Dihydro, l 3-ethylaminoparthenolide; 
l l S, l 1,13 -Dihydro, l 3-methylaminoparthenolide; 
l l S, l 1,13 -Dihydro, l 3-cyclopropylaminoparthenolide; 
1 18,1 1,13 -Dihydro, l 3-propargylaminoparthenolide; 
l l S, l 1,13 -Dihydro, l 3-(N-benzyl-N-ethylamine)partheno 
lide; 
1 18,1 1,13 -Dihydro, l 3-(N-prolyl)parthenolide; 
l l S, l 1,13 -Dihydro, l 3-(S -thiophenolyl)parthenolide; 
l l S, l 1,13 -Dihydro, l 3-(N,N-diethanolamine)parthenolide 
l l S, l 1,13 -Dihydro, l 3-(thiomorpholin-4 -yl)parthenolide; 
l l S, l 1,13 -Dihydro, l 3-(4 -hydroxypiperidin- l -yl)partheno 
lide; 
l l S, l 1,13 -Dihydro, l 3-(1 -methylhomopiperiZin-4 -yl)par 
thenolide; 
l l S, l 1,13 -Dihydro, l 3-(S -mercaptoacetyl)parthenolide; 
l l S, l 1,13 -Dihydro, l 3-(4-(2'-hydroxyethyl)piperidin-l -yl) 
parthenolide; 
1 18,1 1,13 -Dihydro, l 3-(piperaZin-l -yl-4-carboxaldehyde) 
parthenolide; 
1 18,1 1,13 -Dihydro, l 3-(4 -benzylpiperidin- l -yl)partheno 
lide; 
1 18,1 1,13 -Dihydro, l 3-(piperidin-l -yl-4-carboxylic 
parthenolide; 
1 18,1 1,13 -Dihydro, l 3-(azetidin-l -yl-3 -carboxylic acid)par 
thenolide; 
1 18,1 1,13 -Dihydro, l 3-(S-cysteinyl)parthenolide; 
1 18,1 1,13 -Dihydro, l 3-(4-(piperidin- l '-yl)piperidin- l -yl)) 
parthenolide; and 
1 1S, 1 l ,13 -Dihydro, l 3-diallylaminoparthenolide. 
Those of skill in the art Will recognize that the invention 
comprises compounds that may contain one or more chiral 
centers on, for example, the parthenolide C-11 and thus can 
exist as racemic mixtures as pure diastereomers, or as pure 
enantiomers. For many applications, it is preferred to carry 
out stereoselective synthesis and/or to subject the reaction 
product to appropriate puri?cation steps so as to produce 
substantially stereochemically pure or optically pure materi 
als. Suitable stereoselective synthetic procedures for produc 
ing stereochemically pure or optically pure materials are well 
known in the art, as are procedures for resolving racemic 
mixtures into their optically pure enantiomers. 
The present invention further provides for compounds hav 
ing formula (I), or a pharmaceutically acceptable salt thereof, 
Wherein Z is a group that is converted to :CH2 under physi 
ological conditions during or after administration to a mam 
malian patient, thereby yielding a methylene group. In par 
ticular embodiments X1, X2 and X3 are 0; R5, R6, R7, R9, and 
R10 are H; R4 and R8 are 4CH3; and Z is optionally substi 
tuted C1_8 straight-chained or branched aliphatic, optionally 
containing 1 or more double or triple bonds, Wherein one or 
more carbons are optionally replaced by R* Wherein R* is 
optionally substituted cycloalkyl, heterocycloalkyl, aryl or 
heteroaryl; an amino acid residue, H, 4CN, 4C(O)i, 
4C(O)C(O)i, 4C(O)NRli, 4C(O)NR1NR2i, 4C(O) 
acid) 
of, ioqok, iNRlCOZi, foi, iNRlC(O) 
NRL, A)C(O)NRli, iNRlNRZi, iNR1C(O)i, 
isi, isoi, isozi, iNRli, iSOZNRli, 
iNRlRZ, or iNRlSOZi, wherein R1 and R2 are indepen 
dently selected from H and optionally substituted aliphatic, 
cycloalkyl, heterocycloalkyl, aryl or heteroaryl. In preferred 
embodiments Z is iCH2N(CH3)2, 4CH2N(H)(C(CH3)3), 
%H2N(CH2CH3)2, iCH2N(CH2CH:CH2)2, %H2 
azetidine, iCHz-pyrrolidine, iCHZ-piperidine, 4CH2-ho 
mopiperidine, 4CH2-heptamethyleneimine, iCH2-4-me 
thylpiperidine, 4CH2-morpholine, iCHz-pyrrolidine, 
4CH2-proline, 4CH2-thiophenol, 4CH2-diethanolamine, 
4CH2-hydroxypiperidine, 4CH2-methylhomopiperaZine, 
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iCHZ-thiomorpholine, iCHZ-mercaptoacetic acid, 
iCHZ-benzylpiperidine, 4CH2-piperidine-4-carboxylic 
acid, 4CH2-azetidine-3-carboxylic acid, 4CH2-piperidi 
nylpiperidine, or iCHZ-cysteine. 
The present invention further provides for compounds hav 
ing formula (I), or a pharmaceutically acceptable salt thereof, 
Wherein Z is CH2N(CH3)2 Which under physiological condi 
tions during or after administration to a mammalian patient, 
undergoes mono- or di-demethylation; conversion to :CH2, 
or cysteine or protein conjugation. In particular embodi 
ments, X1, X2 and X3 are 0; R5, R6, R7, R9, and R10 are H; R4 
and R8 are iCH3; 
The present invention further provides compounds 
Wherein the parthenolide based derivatives of formula (I) 
form dimers or duplexes With another molecule of formula (I) 
or With basic nitrogen-containing synergistic anticancer drug 
molecules such as 5-?uorouracil, cytarabine, mytomycin C, 
Doxorubicin and Daunorubicin. Accordingly, the present 
invention provides compounds of the general formula (II): 
(11) 
Where L is a linker, as de?ned above, and W is a molecule 
With anti-cancer grthh activity. Where W is another par 
thenolide derivative of formula (I), the present invention pro 
vides compounds of formula (III): 
Where R'4, R's, R'6, R'7, R's, R'9, R'lo, X'l, X'2 and X'3 are 
independently as de?ned above for their counterparts, R6, R7, 
R8, R9, R10, X1, X2 and X3; and L is a linker, as de?ned above. 
Preferred linkers include optionally substituted alkyl and 
amine groups. In one particular embodiment, L is iCHzN 
(R)CH2i, Where R is as de?ned above. Included are phar 
maceutically acceptable salts formed With inorganic and/or 
organic acids, as de?ned above for compounds of formula (I). 
In accordance With another embodiment of the invention, 
the methods for the preparation of the amino analogs 
described in this invention are disclosed in Schemes I and II. 
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Scheme I 
HNRIRZ 
solvent, base 
temp erature 
S cheme II 
solvent, 
has e 
temperature 
In the above scheme, the solvent is selected from a loW alkyl 
alcohol, such as methanol, ethanol, propanol, isopropanol, 
n-butanol, tert-butanol, and chloroform, methylene chloride, 
benzene, toluene, tetrahydrofuran, dioxane, 1,2-dimethoxy 
ethane, pyridine, carbon tetrachloride, diethyl ether, tert-bu 
tyl methyl ether and/or the mixture of two or more of the 
solvents listed above. The base is selected from a low trialky 
lamine, such as trimethylamine, triethylamine, tripropy 
lamine, and tributylamine, and pyridine, 2-, 3-, and 4-pi 
colines, 2-, 3-, and 4-dimethylaminopyridines. The 
temperature is selected from —20° C. to 130° C. The reaction 
time required to effect the desired coupling reaction can vary 
Widely, typically falling in the range of 30 min to 24 hours. 
Puri?cation can be achieved by a variety of techniques, such 
as, liquid chromatography through neutral or basic silica gel, 
bonded silica gel phases such as octadecylsilica, octylsilica 














